Share This Page
Calculi Dissolution Agent Drug Class List
✉ Email this page to a colleague
Drugs in Drug Class: Calculi Dissolution Agent
Market dynamics and patent landscape for calculi dissolution agents (CDAs)
Executive summary: Calculi dissolution agents are niche, targeted small-molecule therapies used to dissolve specific types of urinary stones, typically uric acid stones and, depending on labeling and geography, other stone chemistries. The patent landscape is concentrated in (1) urinary alkalinization salts and (2) formulations and dosing regimens that support sustained, stone-dissolving urinary conditions. Competitive pressure is mainly from low-cost generics of alkalinizing salts and repurposed, off-patent products; new entrants typically rely on formulation/IP for branded longevity rather than new molecular entities. Litigation exposure is usually limited to formulation and method-of-use patents tied to pH targets and sustained-release delivery, rather than broad composition-of-matter coverage.
This analysis covers the CDA category as a class-level market and IP construct: alkalinizing agents used to increase urinary pH to promote dissolution of uric acid calculi (and related chemistries where supported), and formulation patents that extend exclusivity around dosing, sustained release, and combination regimens.
What calculi dissolution agents (CDAs) are used to dissolve and how does that shape demand?
Featured answer: CDA demand is driven by the prevalence of dissolvable stone subtypes (especially uric acid), clinician selection based on stone composition, and payer coverage that ties reimbursement to confirmed chemistry.
Stone chemistry determines treatability
CDAs work only when the urine chemistries needed for dissolution are achievable and maintained long enough to reduce stone burden. In practice, patient selection is constrained by:
- Confirmed or strongly suspected stone type (uric acid is the primary target in most markets).
- Ability to achieve and sustain urinary alkalinization without unacceptable adverse effects.
- Need to avoid delays for stones unlikely to dissolve, balancing dissolution vs. procedural pathways.
What conditions create the largest market pull?
- Chronic, recurrent stone formers who develop a pattern of uric acid stones and can maintain long-term alkalinization.
- Settings favoring conservative management (when stones are smaller, non-obstructive, and dissolution is clinically plausible).
- Payers emphasizing outpatient therapy where dissolution avoids surgery.
What conditions reduce CDA utilization?
- Mixed composition stones.
- Obstruction, infection, or complicated anatomy where dissolution is clinically inferior to intervention.
- Failure to maintain urinary pH due to adherence or tolerability.
Deliverability and adherence are commercial levers
Because CDAs require sustained urinary chemistry, formulations that improve palatability, reduce dosing frequency, and enable consistent urinary pH trajectories tend to win share even in crowded markets.
How do patent estates for CDAs typically look: composition, formulations, and method-of-use?
Featured answer: CDA IP estates are usually not dominated by broad “killer” composition-of-matter patents; they concentrate in formulation patents (salt forms, particle size, release profiles) and method-of-use claims tied to achieving urinary pH targets over time.
Typical IP layers in CDAs
- Composition of matter
- Salt form patents (specific counterions, hydrates/solvates) or new chemical entities if present.
- Formulation and manufacturing method
- Sustained-release tablets/granules
- Granulation and tablet compression processes
- Coating technologies that stabilize in gastric conditions and release in intestines
- Method-of-use
- Dosing regimens to maintain urinary pH in a defined window
- Targeted dosing by baseline urinary chemistry
- Combination regimens (for example, alkalinizer plus inhibitor or adjunct)
Why method-of-use matters commercially
Clinicians and payers buy outcomes. Method-of-use claims that specify pH targets and monitoring schedules align with “how to use” guidance. That creates a narrower but more enforceable licensing surface against generics attempting to replicate branded dosing.
Where expiration risk concentrates
- First-generation branded salts are often long expired.
- Later-cycle formulation improvements can carry the remaining patent runway.
- Use/regimen claims can expire later than composition, depending on claim priority and prosecution history.
Which companies hold the key patents for calculi dissolution agents in major markets?
Featured answer: The CDA patent landscape is split between originators of branded alkalinization products and firms that later developed sustained-release or fixed-dose formulations. Generic manufacturers generally hold process and formulation IP around their own generic products, but they usually do not own broad “category-defining” CDA composition patents.
Practical holder map (category-level)
- Originator brands: companies that historically commercialized branded urinary alkalinizers and stone dissolution regimens.
- Formulation specialists: firms pursuing sustained-release and dosing optimization patents.
- Generic challengers: manufacturers that file ANDAs for alkalinizer salts when branded patents are expired or claim scope is weak.
Patent holder concentration drivers
- Small number of blockbuster CDA assets makes the patent map less diversified than in large oncology/biologics franchises.
- Patent value hinges on whether claims cover “standard of care” dosing and whether generics must carve out dosage or monitoring instructions.
(Note: This class-level query fan-out cannot be mapped to a reliable list of specific patent numbers and assignees without a defined drug list and jurisdictional Orange Book/Biosimilar references. A complete, citation-backed “who holds what” table requires itemized originator products.)
What is the Orange Book status of calculi dissolution agents, and which patents are listed for FDA approval products?
Featured answer: Orange Book coverage for CDAs is typically anchored to NDA-accepted alkalinizing products. Listed patents often include formulation and method-of-use claims rather than broad composition-of-matter.
Orange Book listing patterns for CDA products
Common Orange Book list types:
- Formulation patents (including specific release profiles)
- Use patents tied to pH targets and dosing windows
- Process or manufacturing-related patents
How to interpret “listed patents” for CDA value
For CDA products, the economic question is not “how many patents are listed,” but:
- Which patents are still in-force by expiration date
- Which patents have claim language that blocks generic labeling (not merely “read on” the active ingredient)
- Whether the generic can obtain approval via a carve-out or a non-infringing label
Why ANDA label design matters
Even when active ingredients are generic, generics can face entry delays if their proposed label must include language that triggers infringement of method-of-use claims. Conversely, if patent language is narrow enough, a generic may launch quickly with a label that avoids infringement.
(A complete Orange Book status table requires drug-by-drug identification and corresponding Orange Book entries.)
When do calculi dissolution agent patents expire, and how long do exclusivity and lifecycle extensions last?
Featured answer: Patent lifecycles for CDAs often show a staggered profile: early composition expiries are followed by later formulation and method-of-use expirations that extend market protection by years.
Typical CDA exclusivity timeline shape
- Initial filings: earlier composition or salt patents expire first.
- Second-wave filings: later formulation patents (sustained release, coatings, dosing) expire later and may extend “market exclusivity” indirectly via patent listings.
- Regulatory exclusivity: can add limited incremental time if applicable, but in CDAs it is usually less decisive than listed patents.
How lifecycle extensions affect generic entry timing
- If the branded product’s differentiator is sustained release or a dosing regimen, the remaining formulation and use patents become the “entry gate.”
- If those remaining patents have narrow claim scope, generics may launch while accepting labeling constraints or relying on non-infringing administration differences.
(A date-specific timeline needs each NDA/product and its listed patent expiration dates.)
What patent litigation affects calculi dissolution agents: Paragraph IV, injunction risk, and settlements?
Featured answer: CDA litigation tends to be low-volume but can determine entry timing when patents still cover dosing regimens, release technologies, or method-of-use pH targets. Settlements typically structure launch dates rather than ongoing design-around litigation.
Common litigation pathways
- Paragraph IV ANDA challenges: when Orange Book-listed patents remain in force.
- Infringement disputes around method-of-use: generics argue label design and dosing differences avoid infringement.
- Design-around around formulation: sustained-release claims can drive disputes about dissolution profiles and release kinetics.
Settlement dynamics
In niche categories like CDAs:
- Settlement agreements often set a specific launch date or require label carve-outs.
- Brand firms may enforce only a subset of listed patents, focusing on those with the cleanest claim-to-product overlap.
(A litigation status map requires specific case dockets and patents; without a drug list, a complete litigation summary cannot be produced.)
How does generic entry risk work for calculi dissolution agents: what can generics do to avoid infringement?
Featured answer: Generic risk is usually tied to whether the branded “protected instruction” (pH window, dosing frequency, monitoring) and protected release profile are replicated in the proposed generic label and formulation.
Primary generic entry barriers
- Method-of-use and dosing regimen constraints
- pH target windows
- monitoring schedule language
- Formulation and release profile claims
- release kinetics and delivery system features
- Combination regimens
- if the branded CDA uses a fixed-dose combination, generics may need to design around combination claims
What typically enables faster generic entry
- Expiration of formulation and use patents.
- Label redesign that avoids protected pH targets or shifts to non-infringing dosing instructions.
- Technical formulation differences that avoid infringement of release-related claims.
What formulations are protected by CDA patents: immediate vs sustained release, salt forms, and coatings?
Featured answer: The most enforceable CDA formulation patents usually cover sustained release, specific salt forms/hydration states, and coatings that preserve release characteristics and support stable urine pH maintenance.
Formulation clusters in CDA IP
- Sustained-release tablets intended to smooth urinary pH dynamics.
- Granule/pellet-based systems to control dissolution and absorption.
- Specific counterions and hydration states that impact solubility and stability.
- Coatings to delay release and reduce gastrointestinal side effects that harm adherence.
Why sustained release creates stronger infringement hooks
Release profile claims tie directly to how the dosage form dissolves, absorbed, and produces urinary effects. That makes them more likely to generate technical infringement disputes during ANDA litigation.
How do CDAs compare with procedural treatments and other stone therapies from a market-access perspective?
Featured answer: Market adoption of CDAs depends on payer willingness to cover long-duration outpatient alkalinization in exchange for avoiding procedures, with clinical pathways that require stone chemistry verification.
Competitive substitutes
- Urologic procedures: lithotripsy, ureteroscopy, percutaneous interventions.
- Symptomatic management: analgesics, alpha-blockers in selected stone cases (not dissolution per se).
- Other targeted regimens: depending on stone type.
Economic trade-off that drives payer decisions
- CDA is typically lower cost per day but requires longer treatment periods and monitoring.
- Procedures are higher upfront costs but resolve stone burden quickly.
How patent landscape affects payer incentives
If branded CDAs retain patent exclusivity via formulation/use patents, payer formularies may see higher prices and push utilization management:
- prior authorization
- step therapy (procedural vs dissolution thresholds)
- requirements for stone composition confirmation
What biologics or biosimilars compete with CDAs?
Featured answer: No meaningful biosimilar category directly competes with CDAs because CDAs are small-molecule alkalinization or related dissolution agents, not biologics.
Market impact
- Competitive pressure is from generics and procedural care rather than biosimilars.
Key risks and investment signals across the calculi dissolution agent market
Featured answer: The CDA sector is attractive only where product differentiation is protected by enforceable formulation or method-of-use claims; otherwise, generic price compression dominates quickly after major patent expirations.
Risk checklist for CDA investors and litigators
- Whether remaining patents map cleanly to how clinicians dose and monitor.
- Whether the branded differentiator is sustained-release delivery or dosing regimen language that generics must copy.
- Whether patents are broad enough to cover real-world administration patterns or are narrow enough to be designed around.
- Whether the commercial strategy depends on continued exclusivity or on faster time-to-entry and lower cost once generics launch.
Opportunity profile
- Strongest opportunities come from lifecycle-protected delivery systems and well-defined method-of-use claims aligned with clinical guidelines and pH targets.
- Weak opportunities come from category-wide reliance on the active ingredient alone once that ingredient is off-patent.
Key Takeaways
- CDA demand is concentrated in patient subsets with dissolvable stone chemistry, especially uric acid stones, and is sensitive to clinician selection and payer coverage rules.
- The patent estate for CDAs typically skews toward formulation and method-of-use patents that support sustained urinary alkalinization, with broad composition-of-matter protection often already expired.
- Generic entry risk is mainly driven by whether generics can avoid infringing method-of-use label instructions and protected release profiles.
- Litigation and Paragraph IV challenges in CDAs are usually less frequent than in mainstream therapeutic categories but can be decisive around remaining formulation/use patents.
- Market winners tend to be those with enforceable lifecycle IP and clinical value tied to dosing consistency and tolerability.
FAQs
-
What clinical endpoints do CDA patent claims typically align with?
Endpoints usually map to urinary pH targets over time and stone dissolution proxies, which translate into enforceable dosing instructions and monitoring schedules. -
Do CDA patents protect the active ingredient or the dosage regimen?
In most CDA families, the strongest enforceability is more likely tied to method-of-use pH/dosing regimens and formulation release profiles than to broad active-ingredient composition. -
What are the main reasons generics of CDAs face delayed launch despite expired active-ingredient patents?
Remaining Orange Book-listed method-of-use or formulation patents can force label carve-outs or require non-infringing dosing and delivery-system changes. -
How can sustained-release formulations affect patent scope in CDA litigation?
Sustained-release and release-kinetic claims create technical infringement questions around dissolution curves, absorption timing, and urinary pH trajectories. -
Which CDA strategy reduces both regulatory and IP entry barriers for competitors?
Competitors typically reduce IP exposure by designing non-infringing label language and formulations that do not reproduce protected release kinetics.
References
(No citations provided because the prompt did not specify a drug list, NDA numbers, jurisdictions, or Orange Book entries required to generate a complete, accurate, citation-supported patent and litigation landscape.)
More… ↓
